SUSTAINED REDUCTION IN URINARY CALCIUM DURING LONG-TERM TREATMENT WITH SLOW RELEASE NEUTRAL POTASSIUM PHOSPHATE IN ABSORPTIVE HYPERCALCIURIA

Autor:	Howard J. Heller, Charles Y.C. Pak, Neil A. Breslau, Alfredo A. Reza-Albarran
Rok vydání:	1998
Předmět:	Calcium metabolism medicine.medical_specialty business.industry Urology Potassium Sodium chemistry.chemical_element Calcium Phosphate medicine.disease Urinary calcium chemistry.chemical_compound Endocrinology chemistry Potassium phosphate Internal medicine medicine Hypercalciuria business
Zdroj:	Journal of Urology. 159:1451-1456
ISSN:	1527-3792 0022-5347
DOI:	10.1097/00005392-199805000-00006
Popis:	Purpose: We tested whether UroPhos§ §Mission Pharmacal, San Antonio, Texas.-K a new slow release neutral form of potassium phosphate (155 mg. phosphate, 8 mEq. potassium per tablet) in a dose of 4 tablets twice daily absorptive hypercalciuria, a major cause of nephrolithiasis characterized by excessive intestinal calcium absorption accompanied in some patients by excessive bone loss.Materials and Methods: A total of 25 patients with absorptive hypercalciuria were studied in a 4-year, prospective, open trial with UroPhos-K at yearly intervals during a 4-day inpatient physiological study with a constant metabolic diet containing 400 mg. calcium, 100 mEq. sodium and 800 mg. phosphate daily.Results: Treatment with UroPhos-K caused a sustained, marked reduction in urinary calcium (264 to 181 mg. daily). Fractional47 calcium absorption decreased modestly (74.0 to 64.6%) commensurate with a reduction in serum 1,25-dihydroxyvitamin D (42 to 34 pg./ml.). Intact parathyroid hormone increased within the norm...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c0e91722a6f43188d1994786a0da9352 https://doi.org/10.1097/00005392-199805000-00006 Zobrazit plný text záznamu